We recently got a double dose of news regarding cancer collaborations, first with Bristol Myers Squibb and Celldex working together on a phase 1/2 study for two of their oncology drugs, and also now with AstraZeneca (NYSE:AZN) and Incyte (NASDAQ:INCY) collaborating on a phase 1/2 study combining AstraZeneca's MEDI4736 (an anti-PD-L1 checkpoint inhibitor) and Incyte's INCB24360. The two companies will collaborate a number of solid tumors, including potentially non-small cell lung cancer, pancreatic caner, metastatic melanoma, and carcinoma of the head and neck.
Unlike Bristol's deal, this one is non-exclusive, as Incyte is already testing its drug with Merck's MK-3475. The hope is that a two-drug combination may prove more effective than a single therapy.
In this video, from Wednesday's Market Checkup , the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson look at this partnership and the potential benefits to AstraZeneca and Incyte.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.